By Dr. Michael Kwabla ADAFLAGBE In today’s interconnected business world, both multinational corporations and local Ghanaian ...

Forbes contributors publish independent expert analyses and insights. I am the Kester and Brynes Professor at Columbia Business School and a Chazen Senior Scholar at the Jerome A. Chazen Institute for ...

Food & Drug Administration (FDA) guidance is just now addressing the challenges of manufacturing cell and gene therapy (CGT) products with a proposed draft guidance, Manufacturing Changes and ...

The European Union is strengthening its pioneering role in the regulation of biosimilars by further developing the basic rules for determining the levels of compatibility for this group of drugs.

This is the third in a four-part series by Ralph Thurm and Nick De Ruiter examining Sustainability Context. The GRI Content Principles — Sustainability Context (part two of this series), Materiality ...

Removing the loophole for salary differentials and staff qualifications is the first step toward a more accurate calculation of school resources. Congress will have the opportunity this year as it ...

At its inception over 40 years ago, the flagship Title I program of the Elementary and Secondary Education Act of 1965 was intended as the federal government’s way of giving high-poverty schools a leg ...

We’re not sure if we’re having another epiphany, or merely looking at the world a little bit differently, but we have some thoughts on an area of accounting practice and theory that we’d like to share ...

Clinical trials required by European regulators to compare biosimilar products with corresponding biologic brands are surplus to requirements and may even be a barrier for the development of ...

When Congress passed the No Child Left Behind Act in 2001, it rewrote much of the Elementary and Secondary Education Act, increasing the amount of testing required and demanding that states hold ...